Compromised TGFβ signaling and DNA repair primes immune poor tumors response to immune checkpoint blockade by activating NK cells

被引：0
|
作者：
Moore, Jade T.
Gkantalis, Jim
Guix, Ines
Barcellos-Hoff, Mary Helen
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6651
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6651
引用
收藏
页数：2
相关论文
共 50 条
  • [11] One checkpoint may hide another: inhibiting the TGFβ signaling pathway enhances immune checkpoint blockade
    Gupta, Aditi
    Budhu, Sadna
    Merghoub, Taha
    HEPATOBILIARY SURGERY AND NUTRITION, 2019, 8 (03) : 289 - 294
  • [12] Epigenetic changes in T cells in response to immune checkpoint blockade
    Goswami, Sangeeta
    Chen, Jianfeng
    Zhao, Hao
    Zhang, Xuejun
    Sharma, Padmanee
    CANCER RESEARCH, 2016, 76
  • [13] Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade
    Guan, Yaping
    Feng, Dongfeng
    Yin, Beibei
    Li, Kun
    Wang, Jun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [14] Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
    Yujiao Wang
    Xi Jiao
    Shuang Li
    Huan Chen
    Xin Wei
    Chang Liu
    Jifang Gong
    Xiaotian Zhang
    Xicheng Wang
    Zhi Peng
    Changsong Qi
    Zhenghang Wang
    Yanni Wang
    Na Zhuo
    Jianling Zou
    Henghui Zhang
    Jian Li
    Lin Shen
    Zhihao Lu
    Cancer Biology & Medicine, 2022, 19 (08) : 1139 - 1149
  • [15] Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
    Wang, Yujiao
    Jiao, Xi
    Li, Shuang
    Chen, Huan
    Wei, Xin
    Liu, Chang
    Gong, Jifang
    Zhang, Xiaotian
    Wang, Xicheng
    Peng, Zhi
    Qi, Changsong
    Wang, Zhenghang
    Wang, Yanni
    Zhuo, Na
    Zou, Jianling
    Zhang, Henghui
    Li, Jian
    Shen, Lin
    Lu, Zhihao
    CANCER BIOLOGY & MEDICINE, 2022, 19 (08) : 1139 - 1149
  • [16] Effector B cells and tertiary lymphoid structures predict response to immune checkpoint blockade in solid tumors
    Reddy, Sangeetha M.
    Helmink, Beth
    Gao, Jianjun
    Zhang, Shaojun
    Yizhak, Keren
    Sade-Feldman, Moshe
    Basar, Rafet
    Blando, Jorge
    Han, Guangchun
    Gopalakrishnan, Vancheswaran
    Zhao, Hao
    Liu, Wenbin
    Tawbi, Hussein
    Amaria, Rodabe
    Davies, Michael
    Gershenwald, Jeffrey
    Burton, Elizabeth M.
    Allison, James
    Tetzlaff, Michael
    Rezvani, Katy
    Hacohen, Nir
    Sharma, Padmanee
    Wang, Linghua
    Wargo, Jennifer
    CANCER RESEARCH, 2019, 79 (13)
  • [17] Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
    Horowitch, Brooke
    Lee, Daniel Y.
    Ding, Min
    Martinez-Morilla, Sandra
    Aung, Thazin Nwe
    Ouerghi, Feriel
    Wang, Xueting
    Wei, Wei
    Damsky, William
    Sznol, Mario
    Kluger, Harriet
    Rimm, David L.
    Ishizuka, Jeffrey J.
    CLINICAL CANCER RESEARCH, 2023, 29 (15) : 2908 - 2918
  • [18] Epigenetic changes in T cells in response to immune checkpoint blockade.
    Goswami, Sangeeta
    Zhao, Hao
    Zhang, Xuejun
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [19] Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade
    Wang, Chensu
    Cui, Ang
    Bukenya, Maurice
    Aung, Aereas
    Pradhan, Dikshant
    Whittaker, Charles A.
    Agarwal, Yash
    Thomas, Ayush
    Liang, Simon
    Amlashi, Parastoo
    Suh, Heikyung
    Spranger, Stefani
    Hacohen, Nir
    Irvine, Darrell J.
    CELL REPORTS, 2021, 37 (08):
  • [20] Response to immune checkpoint inhibition in a meningioma with DNA mismatch repair deficiency
    Nguyen, Minh P.
    Bonnin, Damian Almiron
    Mirchia, Kanish
    Chen, William C.
    Goldschmidt, Ezequiel
    Braunstein, Steve E.
    Perry, Arie
    Raleigh, David R.
    Bush, Nancy Ann Oberheim
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
12345